Aeglea BioTherapeutics, Inc./$SYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Primary listing
Employees
87
Headquarters
Website
SYRE Metrics
BasicAdvanced
$909M
-
-$2.85
2.83
-
Price and volume
Market cap
$909M
Beta
2.83
52-week high
$21.03
52-week low
$10.91
Average daily volume
467K
Financial strength
Current ratio
6.487
Quick ratio
6.382
Profitability
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-28.48%
Return on equity (TTM)
-49.83%
Valuation
Price to book
3.03
Price to tangible book (TTM)
3.03
Price to free cash flow (TTM)
-5.537
Free cash flow yield (TTM)
-18.06%
Free cash flow per share (TTM)
-2.718
Growth
Earnings per share change (TTM)
-183.33%
3-year earnings per share growth (CAGR)
-55.03%
10-year earnings per share growth (CAGR)
-39.94%
Bulls say / Bears say
Strong cash runway supports development, with $526.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, expected to fund the company into the second half of 2028 (Globe Newswire).
Advancing pipeline with the start of the Phase 2 SKYLINE-UC platform trial for ulcerative colitis and an on-schedule Q3 launch of the Phase 2 SKYWAY-RD basket study for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, setting up the company for up to nine proof-of-concept readouts over the next two years (Globe Newswire).
Interim Phase 1 results for two next-generation TL1A antibodies show strong tolerability, pharmacokinetics supporting quarterly or twice-yearly dosing, and full target engagement for 20 weeks, highlighting Spyre’s potential to deliver best-in-class TL1A inhibitors in IBD and rheumatic diseases (Globe Newswire).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?
Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $909M as of September 18, 2025.
What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of September 18, 2025.
Does Aeglea BioTherapeutics, Inc. stock pay dividends?
No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Aeglea BioTherapeutics, Inc. dividend payment date?
Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aeglea BioTherapeutics, Inc.?
Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 2.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.